SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellass Phase 3 REGAL trial for its AML candidate GPS is nearing the 80th-event milestone that triggers final efficacy analysis, while the CEOs comments and favorable remarks from healthcare executives have intensified attention. Traders are largely bullish and view the prolonged survival tail as supportive, though bearish participants question the trials design, dosing changes and delayed event count; the 80th event and unblinded data remain unconfirmed.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops preliminary Q2 update and convertible-note exchange amendment are driving attention, with traders focusing on improved operating profitability and capped share dilution through a larger cash settlement. Bulls view the changes as supportive of buybacks and potential short covering, while skeptics point to weaker sales, remaining debt and unusual warrant activity as reasons for caution; the warrant move has also fueled unconfirmed squeeze speculation.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Escalating U.S.-Iran tensions and uncertainty around Strait of Hormuz shipping are driving attention to CCL through their impact on oil prices, fuel costs, and travel demand. Traders are split between bearish concerns over geopolitical risk, debt, and persistent selling, and bullish views that strong bookings, deleveraging, dividends, and buybacks leave the shares undervalued.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is drawing attention ahead of its upcoming earnings release, with traders positioning for a potentially sharp reaction and debating whether strong AI-driven cybersecurity demand and recent sector strength justify its elevated valuation. Bullish participants expect a beat and raised guidance, while others are buying puts or anticipating a post-earnings selloff.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is drawing attention after an institutional financing that supports the ROBBIN Phase 3 trial of BOT/BAL in MSS colorectal cancer, alongside encouraging neoadjuvant NEST data and the shift away from BATTMAN. Traders view the funding and investor involvement as a potential turnaround, while skeptics focus on warrant-related dilution, management concerns, and the long timeline to meaningful Phase 3 results.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Hawkish Federal Reserve signals from Kevin Warsh and rising expectations for a potential rate hike are driving debate around DIA, alongside elevated Treasury yields and inflation concerns. Traders are split between expecting a near-term pullback as higher rates pressure equities and viewing any weakness as a buying opportunity, while geopolitical tensions and oil prices add to volatility concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on Dr. Patrick Soon-Shiongs Sean Spicer interview and comments that the UAE may expand ANKTIVA access to lymphopenia and broader cancer indications, alongside Germanys commercial rollout. Traders are broadly bullish on international growth and a potential short squeeze, while skeptics note that expanded approvals and revenue remain unconfirmed and that U.S. FDA decisions are still pending.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Reported U.S.-Venezuela oil arrangements and Chevrons potential expansion of its Venezuelan joint ventures are driving attention, with traders portraying CVX as a likely beneficiary of increased production access. The community is divided between bullish views on the strategic opportunity and skepticism that the reports are unconfirmed and that Venezuelan output would recover quickly, while broader IranHormuz supply risks continue to influence oil sentiment.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

A mixed quarterly reportan earnings miss despite stronger revenue, raised full-year guidance, and record power/electrification backloghas driven attention and a sharp selloff. Traders are split between viewing the drop as an overreaction and buying opportunity, versus questioning valuation, execution, tariff exposure, and weakness in the wind segment; the longer-term debate centers on GE Vernovas role in supplying power and grid infrastructure for AI data centers.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is drawing attention after CFO Julia Donnelly announced plans to leave for an early-stage company, with Vikram Naidu appointed interim CFO while an external search begins. Traders are debating whether the transition signals slowing growth and added uncertainty, although the company said her departure is not related to operations, policies, or accounting matters.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This transcript is brought to you by Benzinga APIs. For real-time access toread more...

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetiks artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology...

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received an average rating of "Hold" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst...

Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6%

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling 96,493 shares, a...

MiNK Therapeutics reported a net loss of $3.1 million, or $0.62 per share, for the second quarter of 2026, with cash and cash equivalents totaling $8.8 million as of June 30.

MiNK Therapeutics faces financial pressure from a net loss and declining cash reserves, while the clinical program remains in preliminary stages without regulatory approval or confirmed efficacy for agenT-797.

MiNK Therapeutics advanced its lead candidate into randomized clinical trials with positive initial observations and launched a strategic international access program to generate revenue and build scalable infrastructure for agenT-797.

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

MiNK Therapeutics Inc

Why Did INKT Stock Jump 30% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

INKT MiNK Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest INKT News